

JUL 23 2002

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 1 of 3

Complete if Known

Application Number	09/721,341
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket Number	019934-000711US

U.S. PATENT DOCUMENTS

Examiner	Cite No. ¹	Document Number Number Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BBB	AA	20010016336 A1	08-23-2001	Ellis	
	AB	5,032,445	08-03-1990	Lal et al.	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³	Number ⁴ Kind Code ⁵ (if known)				
	AC	EP	0 899 332 A2	03-03-1999	Smith Kline Beecham		
	AD	PCT	WO 99/24463 A2	05-20-1999	Incyte Pharmaceuticals, Inc.		
BBB	AE	PCT	WO 99/33876 A1	07-08-1999	Asahi Kasei Kogyo Kabushiki		abstract only
	AF	PCT	WO 99/52945 A2	10-21-1999	Millenium Pharmaceuticals, Inc.		
BBB	AG	PCT	WO 00/26369 A1	05-11-2000	Chiron Corporation		
BBB	AH	PCT	WO 00/64941 A2	11-02-2000	Curagen Corporation		

Examiner
Signature

Bridget E. Bunner

Date
Considered


2/5/2003

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

DE 7076560 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Institute for Technology

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 3

Complete if Known

Application Number	09/721,341
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket Number	019934-000711US

RECEIVED
JUL 26 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
Bob	AI	GenBank Accession Number AA215577; August 13, 1997, NCI - CGAP.	-
	AJ	GenBank Accession Number AF233281; May 22, 2000, Gosling et al.	-
	AK	GenBank Accession Number AI131555; October 26, 1998, NCI - CGAP.	-
	AL	GenBank Accession Number AI769466; June 28, 1999, NCI - CGAP.	-
	AM	GenBank Accession Number AR003970; December 10, 1998, Birkenbach et al.	-
	AN	GenBank Accession Number AW190975; November 22, 1999, NCI - CGAP.	-
	AO	GenBank Accession Number E12852; June 24, 1998, Tokugawa et al.	-
	AP	GenBank Accession Number H67224; October 27, 1995, Hillier et al.	-
	AQ	DATABASE EMBL Accession No. Q9NPB9; 1 October 2000.	-
	AR	DATABASE EMBL Accession No. Y30125; 14 October 1999, Ishimaru et al.	-
	AS	DAIRAGHI, DANIEL J., et al. Chemokine Receptor CCR3 Function Is Highly Dependent on Local pH and Ionic Strength; The Journal of Biological Chemistry; November 7, 1997; pp. 28206-28209; Volume 272, No. 45	-
Bob	AT	DAIRAGHI, DANIEL J. et al.; HHV8-encoded vMIP-I Selectively Engages Chemokine Receptor CCR8; The Journal of Biological Chemistry; July 30, 1999; pp. 21569-21574; Volume 274, No. 31	-
	AU	GOSLING, JENNIFA, et al.; Cutting Edge: Identification of a Novel Chemokine Receptor That Binds Dendritic Cell and T Cell-Active Chemokines Including ELC, SLC, and TECK; The Journal of Immunology; 2000; pp. 2851-2856	-
Bob	AV	HULME, E.C., editor; Receptor-Ligand Interactions A Practical Approach; 1992; Preface, Table of Contents, Chapters 6, 7, 8 and 9; pp. viii-xv and 213-263; IRL Press at Oxford University Press Inc., New York, New York	-
Bob	AW	MATSUOKA, ICHIRO et al.; Identification of Novel Members of G-Protein Coupled Receptor Superfamily Expressed in Bovine Taste Tissue; Biochemical and Biophysical Research Communications; July 15, 1993; pp. 504-511; volume 194, No. 1	-
Bob	AX	O'DOWD, BRIAN F., et al.; A novel gene codes for a putative G protein-coupled receptor with an abundant expression in brain; FEBS Letters 1996; pp 325-329	-

Examiner
Signature

Bridget E. Bunner


Date
Considered

2/5/2003

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7076560 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 3

C mplete if Known

Application Number	09/721,341
Filing Date	November 21, 2000
First Named Inventor	Gosling, Jennifa
Art Unit	1647
Examiner Name	Bunner, Bridget E.
Attorney Docket Number	019934-000711US

RECEIVED
JUL 26 2002
TECH CENTER 1600/2900

OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS

Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	AY	SCHWEICKART, VICKI L. et al.; CCR11 Is a Functional Receptor for the Monocyte Chemoattractant Protein Family of Chemokines, The Journal of Biological Chemistry, March 31, 2000, pp. 9550-9556, volume 275, No. 13.	
BBB	AZ	SISSORS, DANIEL L., et al.; A Homogeneous Receptor Binding Assay for HTS on FlashPlate® Plus; NEN® Life Science Products, Inc.; 1999; pp. 1-7	-
	BA	copy of PCT International Search Report for PCT/US00/28067	-
	BB	copy of PCT International Preliminary Examination Report for PCT/US00/28067	-

considered;
DO NOT PRINT

Examiner Signature	<u>Bridget E. Bunner</u>	Date Considered	<u>2/5/2003</u>
-----------------------	--------------------------	--------------------	-----------------

* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Unique citation designation number. ² Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.
DE 7076560 v1